Multiple Sclerosis

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Register here to gain access to SAGE's 500+ Journals Online

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pachner, A.R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Pachner, A.R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Multiple Sclerosis, Vol. 13, No. 1 suppl, 49-52 (2007)
DOI: 10.1177/1352458507076991

Real-time TaqMan assay for myxovirus resistance protein (MxA) mRNA: a robust marker of interferon beta bioactivity in patients with multiple sclerosis

A.R. Pachner

Department of Neurosciences, University of Medicine and Dentistry of New Jersey, Newark, NJ, USA, pachner{at}umdnj.edu

For many patients suffering from MS, interferon beta (IFNß) is an effective therapeutic option; however, some patients who receive long-term IFNß therapy for relapsing-remitting MS (RRMS) develop neutralizing antibodies (NAbs) that affect IFNß efficacy. It is therefore important to evaluate patients' therapeutic response to IFNß over time. Myxovirus resistance protein A (MxA), a surrogate marker of individual immunologic response to IFNß, may be a useful tool for assessing IFNß immunogenicity. The real-time TaqMan assay for MxA messenger RNA (mRNA) has several distinct advantages, including the ability to amplify and complete quantitative analyses in one step, a high degree of quality control and prior experience and confidence in the field of quantitative viral diagnostics. The real-time TaqMan assay for MxA mRNA can be incorporated as a component of IFNß therapy to evaluate patients during the course of treatment. Multiple Sclerosis 2007; 13: S49—S52. http://msj.sagepub.com

Key Words: gene expression • interferons • multiple sclerosis • myxovirus resistance proteins • neutralizing antibodies • relapsing-remitting • Taq polymerase


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?